Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events

被引:12
|
作者
Zhong, Xiaobo
Lim, Emerson A.
Hershman, Dawn L.
Moinpour, Carol M.
Unger, Joseph
Lee, Shing M.
机构
[1] Columbia Univ, New York, NY USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
关键词
QUALITY-OF-LIFE; STAGE PROSTATE-CANCER; SYMPTOM CLUSTERS; BREAST-CANCER; LUNG-CANCER; FATIGUE; PAIN; ESTRAMUSTINE; MITOXANTRONE; EXPERIENCES;
D O I
10.1200/JOP.2015.006106
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Exploring the relationships among adverse events is important because those that arise from a common mechanism are amenable to a common intervention, which can improve symptom management, quality of life, and treatment adherence. To date, symptom cluster studies have used patient-reported data, which are not always available in clinical trials. In this study, we proposed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) to identify adverse event clusters because the CTCAE data are collected as standard practice and can therefore be used when patient-reported outcomes are unavailable. Methods The CTCAE data from a randomized clinical trial conducted by SWOG that compared docetaxel plus estramustine versus mitoxantrone plus predinsone in patients with advanced prostate cancer were used to identify severe adverse event clusters. A variable based hierarchical cluster analysis was conducted using the CTCAE for the 323 patients who experienced at least one grade 3 or higher adverse event. Results A total of 109 adverse event types were captured using the CTCAE. Four clusters had moderate associations: nausea, vomiting, and anorexia (n = 35, r = 0.45); joint/bone (myalgia, arthralgia, and arthritis) and muscle weakness (n = 26, r = 0.29); anemia and transfusion (n = 20, r = 0.38); and neutrophils/granulocytes, febrile neutropenia, and leukocytes/lymphopenia (n = 114, r = 0.29). Two clusters had weak associations: fatigue/malaise/lethargy and dehydration (n = 66, r = 0.12); and constipation, infection without neutropenia, and abdominal pain/cramping (n = 35, r = 0.13). Conclusion Several severe adverse event clusters were identified in patients with advanced prostate cancer. Identifying adverse event clusters using CTCAE data from clinical trials is feasible.
引用
收藏
页码:E270 / E280
页数:11
相关论文
共 50 条
  • [1] Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events.
    Basch, E. M.
    McDonough, T.
    Iasonos, A.
    Siegel, E.
    Culkin, A.
    Kris, M.
    Scher, H. I.
    Schrag, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 471S - 471S
  • [2] Common terminology criteria for adverse events
    Piura, B
    Rabinovich, A
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (04) : 612 - 617
  • [3] Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0
    Chen, Alice P.
    Setser, Ann
    Anadkat, Milan J.
    Cotliar, Jonathan
    Olsen, Elise A.
    Garden, Benjamin C.
    Lacouture, Mario E.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (05) : 1025 - 1039
  • [4] Linguistic Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean
    Cho, Juhee
    Yoon, Junghee
    Kim, Youngha
    Oh, Dongryul
    Kim, Seok Jin
    Ahn, Jinseok
    Suh, Gee Young
    Nam, Seok Jin
    Mitchell, Sandra A.
    [J]. JOURNAL OF GLOBAL ONCOLOGY, 2019, 5
  • [5] Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
    Basch, Ethan
    Reeve, Bryce B.
    Mitchell, Sandra A.
    Clauser, Steven B.
    Minasian, Lori M.
    Dueck, Amylou C.
    Mendoza, Tito R.
    Hay, Jennifer
    Atkinson, Thomas M.
    Abernethy, Amy P.
    Bruner, Deborah W.
    Cleeland, Charles S.
    Sloan, Jeff A.
    Chilukuri, Ram
    Baumgartner, Paul
    Denicoff, Andrea
    St Germain, Diane
    O'Mara, Ann M.
    Chen, Alice
    Kelaghan, Joseph
    Bennett, Antonia V.
    Sit, Laura
    Rogak, Lauren
    Barz, Allison
    Paul, Diane B.
    Schrag, Deborah
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (09)
  • [6] Reliability and Validity of the Korean Language Version of the US National Cancer Institute?s Patient -Reported Outcomes Common Terminology Criteria for Adverse Events
    Yoon, Junghee
    Sim, Sung Hoon
    Kang, Danbee
    Han, Gayeon
    Kim, Youngha
    Ahn, Jinseok
    Oh, Dongryul
    Lee, Eun Sook
    Kong, Sun Young
    Cho, Juhee
    Mitchell, Sandra A.
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2020, 59 (05) : 1082 - +
  • [7] Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
    Chung, Arlene E.
    Shoenbill, Kimberly
    Mitchell, Sandra A.
    Dueck, Amylou C.
    Schrag, Deborah
    Bruner, Deborah W.
    Minasian, Lori M.
    St Germain, Diane
    O'Mara, Ann M.
    Baumgartner, Paul
    Rogak, Lauren J.
    Abernethy, Amy P.
    Griffin, Ashley C.
    Basch, Ethan M.
    [J]. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2019, 26 (04) : 276 - 285
  • [8] Linguistic validation of the Spanish translation of the US National Cancer Institute's Patient- Reported Outcomes version of the Common Terminology Criteria for Adverse Events
    Arnold, Benjamin J.
    Mitchell, Sandra A.
    Lent, Lauren
    Mendoza, Tito R.
    Rogak, Lauren
    Barragan, Natalie
    Willis, Gordon B.
    Medina, Mauricio
    Lechner, Suzanne C.
    Harness, Jay
    Basch, Ethan
    [J]. QUALITY OF LIFE RESEARCH, 2014, 23 : 51 - 52
  • [9] Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study
    Basch, Ethan
    Iasonos, Alexia
    McDonough, Tiffani
    Barz, Allison
    Culkin, Ann
    Kris, Mark G.
    Scher, Howard I.
    Schrag, Deborah
    [J]. LANCET ONCOLOGY, 2006, 7 (11): : 903 - 909
  • [10] Use and misuse of common terminology criteria for adverse events in cancer clinical trials
    Zhang, Sheng
    Liang, Fei
    Tannock, Ian
    [J]. BMC CANCER, 2016, 16